Table 2.
Drugs and natural compounds (N) that affect BCL-w level.
| Drug or compound | Disease model (cell line) | Effective concentration | Effect on BCL-w level | Level of regulation | Reference |
|---|---|---|---|---|---|
| β-asaroneN | β-amyloid-induced rat model of Alzheimer’s disease | 12.5 mg/kg | Up | mRNA protein | 81 |
| 25 mg/kg | |||||
| 50 mg/kg | |||||
| β-amyloid-treated rat pheochromocytoma (PC12) | 15 µg/ml | Up | mRNA protein | 82 | |
| CurcuminN | Breast cancer (MCF-7) | 25 µg/ml | Up | mRNA | 193 |
| 50 µg/ml | |||||
| Breast cancer (MCF-7 and MDA-MB-231) | 5 µM | No effect | protein | 194 | |
| GenisteinN | β-amyloid-treated rat pheochromocytoma (PC12) | 25 µM | Up | mRNA | 195 |
| Phenethyl isothiocyanate (PEITC)N | Sprague–Dawley rats (hepatic cells) | 150 µmol/kg | Up | mRNA | 196 |
| Cisplatin | HNSCC (JHU-029) | 10 µg/ml | Down | protein | 133 |
| Coptidis Rhizoma extractN | Melanoma (A2058, UACC257 and UACC62) | 100 µg/ml | Down | mRNA protein | 197 |
| Cyramza (ramucirumab) | NSCLC (HCC4006) | nd. | Down | protein | 111 |
| Dihydromyricetin N | NSCLC (A549 and H1975) | 75 µM | Down | protein | 198 |
| FisetinN | HCC (Huh-7) | 60 µM | Down | protein | 199 |
| IsoledeneN | Colorectal cancer (HCT-116) | 8–28 µg/ml | Down | mRNA | 200 |
| Phenazine-1-carboxamide (PCN)N | Breast cancer (MDA-MB-231) NSCLC (A549) | nd. | Down | mRNA protein | 201 |
| SanguinarineN | N-Myc-negative neuroblastoma (SH-SY5Y) | 5 µM | Down | mRNA | 202 |
| Tanshinone IIAN | Ovarian cancer (A2780) | 150 µM | Down | protein | 203 |
| QuercetinN | Mouse neuroblastoma (N2a) | 20 µM | Down | mRNA | 204 |
| 40 µM |
HCC hepatocellular carcinoma, HNSCC head and neck squamous cell carcinoma, NSCLC non-small cell lung cancer, nd. not determined.